![Right to Try edges closer to becoming federal law libertarians rejoice, but can it solve compassionate use problems?](https://cdn.cancerletter.com/media/2018/03/bridge-websmall.jpg)
![Right to Try edges closer to becoming federal law libertarians rejoice, but can it solve compassionate use problems?](https://cdn.cancerletter.com/media/2018/03/bridge-websmall.jpg)
Cover Story
By Matthew Bin Han Ong
Few Washington insiders doubt that a bill that allows terminally ill patients to circumvent FDA as they pursue Hail Mary pass therapies will become the law of the land.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - Otis Brawley discusses health disparities, UChicago pioneering oncologists on the UChicago Cancer Luminaries Podcast